Startups
TOKYO, CAMBRIDGE (UK), August 10, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter Widdowson, Ph.D., “Quethera”) today announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom, that is focused on developing novel treatments for ocular disorders, such as glaucoma.
Overview
Employees
11-50
Founded date
2013
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 4, 2022 | Maris-Tech Ltd. Announces Closing of $17.8 Million Initial Public Offering with Simultaneous Exercise of the Over-Allotment | REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (the “Company”), a B2B provider of intelligent video transmission technology, today announced the closing of its initial public offering, and the simultaneous closing of a p... |
| Feb 2, 2022 | Maris-Tech Ltd. Announces Pricing of $15.5 Million Initial Public Offering | REHOVOT, Israel, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (the “Company”), a B2B provider of intelligent video transmission technology, today announced the pricing of its initial public offering of 3,700,477 common units and pre-fu... |
| Feb 1, 2022 | Maris-Tech Ltd. Announces Pricing of $15.5 Million Initial Public Offering | REHOVOT, Israel, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (the “Company”), a B2B provider of intelligent video transmission technology, today announced the pricing of its initial public offering of 3,700,477 common units and pre-fu... |
| Aug 14, 2018 | Astellas announces acquisition of Cambridge spin-out Quethera | Astellas Pharma Inc. and Quethera Limited have announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma. ... |
| Aug 14, 2018 | Astellas announces acquisition of Cambridge spin-out Quethera | Astellas announces acquisition of Cambridge spin-out Quethera 14-08-2018 Astellas Pharma Inc. and Quethera Limited have announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focuse... |
| Apr 3, 2017 | Cambridge-based spin-offs get Bio-start funding | Cambridge-based spin-offs get Bio-start funding 03-04-2017 After an intensive 10-week competition across the UK, several Cambridge spin-offs have been awarded Bio-start funding, as well as the opportunity to join the UK’s first synthetic bi... |
| Mar 7, 2016 | Quethera Receives Grant from Wellcome Trust Pathfinder Award Scheme | Quethera Ltd, a Cambridge, UK-based gene therapy company, obtained a grant from the Wellcome Trust Pathfinder Award Scheme. The award will assist the company in the optimization and design of its novel gene construct aimed at preventing fur... |
| Jan 11, 2016 | V-Wave Ltd. Announces $28M Series B Financing | |
| Astellas announces acquisition of Quethera | Astellas Pharma Inc. and Quethera Limited announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma. |
Show more
Reviews 0
FAQ about Quethera
When was Quethera founded?
Quethera was founded in 2013.
What has the press written about Quethera?
Parsers VC has collected 11 articles mentioning Quethera, among them “Maris-Tech Ltd. Announces Closing of $17.8 Million Initial Public Offering with Simultaneous Exercise of the Over-Allotment” (Feb 4, 2022) and “Maris-Tech Ltd. Announces Pricing of $15.5 Million Initial Public Offering” (Feb 2, 2022).
Is Quethera still active?
Yes, Quethera is active; its latest activity on Parsers VC dates from Feb 4, 2022.